1888 PressRelease Home	Sign In	Register	About Us	Sitemap

1888 Press Release | Imgen Corporation Press Releases

Imgenex.com - Imgen Corporation Company News Section

Imgen Corporation Information

Dr. Sujay Singh

URL: http://www.imgenex.com

Imgenex Corp. develops and commercializes novel reagents for the scientific study of human biology and disease and for the production of new diagnostic assays and potential therapies of such diseases. These novel reagents include antibodies, gene and protein expression systems, and arrays of various cells and tissues for use in studies of functional genomics. Areas of biological interest at Imgenex include cancer, apoptosis (programmed cell death), molecular signaling pathways, cellular aging, and metabolic and infectious diseases.

Imgen Corporation Press Release -

Imgenex.com

03
AUG

IMGENEX obtains world-wide rights to IL-35

IMGENEX Corporation, a San Diego based company, has obtained exclusive world-wide rights to US Patent no. 5,830,451 from Brigham & Women's Hospital, Boston, to develop and market the EBI3-p35 fusion protein also known as Interleukin 35 (IL-35), for research purposes. IL-35 is a novel IL-12 family cytokine produced by regulatory T cells (Treg) shown to suppress immune response through expansion o

IMGENEX Corporation, a San Diego based company, has obtained exclusive world-wide rights to US Patent no. 5,830,451 from Brigham & Women's Hospital, B ...

28
SEP

Tissue Micro Arrays : A Powerful Solution For Biomarker Validation

IMGENEX is excited to announce the availability of patient survival data for 25 of their most popular slides. This information will enable researchers to identify important prognostic markers and biomarker clusters for characterization of disease progression and patient outcome.

IMGENEX is excited to announce the availability of patient survival data for 25 of their most popular slides. This information will enable researchers ...

29
AUG

IMGENEX Exclusive North America Distributor For Dendritics

IMGENEX is pleased to announce that it has signed an exclusive distribution agreement with Dendritics SAS (Dardilly, France) to make their portfolio of highly characterized and validated monoclonal Dendritic cell research antibodies available to researchers in North America and India.

IMGENEX is pleased to announce that it has signed an exclusive distribution agreement with Dendritics SAS (Dardilly, France) to make their portfolio o ...